Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Dent Res ; 102(6): 616-625, 2023 06.
Article in English | MEDLINE | ID: mdl-36951356

ABSTRACT

Dentinogenesis imperfecta (DI) is the main orodental manifestation of osteogenesis imperfecta (OI) caused by COL1A1 or COL1A2 heterozygous pathogenic variants. Its prevalence varies according to the studied population. Here, we report the molecular analysis of 81 patients with OI followed at reference centers in Brazil and France presenting COL1A1 or COL1A2 variants. Patients were submitted to clinical and radiographic dental examinations to diagnose the presence of DI. In addition, a systematic literature search and a descriptive statistical analysis were performed to investigate OI/DI phenotype-genotype correlation in a worldwide sample. In our cohort, 50 patients had COL1A1 pathogenic variants, and 31 patients had COL1A2 variants. A total of 25 novel variants were identified. Overall, data from a total of 906 individuals with OI were assessed. Results show that DI was more frequent in severe and moderate OI cases. DI prevalence was also more often associated with COL1A2 (67.6%) than with COL1A1 variants (45.4%) because COL1A2 variants mainly lead to qualitative defects that predispose to DI more than quantitative defects. For the first time, 4 DI hotspots were identified. In addition, we showed that 1) glycine substitution by branched and charged amino acids in the α2(I) chain and 2) substitutions occurring in major ligand binding regions-MLRB2 in α1(I) and MLBR 3 in α2(I)-could significantly predict DI (P < 0.05). The accumulated variant data analysis in this study provides a further basis for increasing our comprehension to better predict the occurrence and severity of DI and appropriate OI patient management.


Subject(s)
Collagen Type I, alpha 1 Chain , Collagen Type I , Dentinogenesis Imperfecta , Osteogenesis Imperfecta , Humans , Collagen Type I/genetics , Dentinogenesis Imperfecta/genetics , Genetic Association Studies , Mutation , Osteogenesis Imperfecta/diagnostic imaging , Osteogenesis Imperfecta/genetics
2.
Toxicol In Vitro ; 88: 105558, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36681288

ABSTRACT

BACKGROUND: This systematic review aimed to investigate the in vitro and in vivo effects of phosphatidylinositol-3-kinase (PI3K) inhibitors on head and neck squamous cell carcinoma (HNSCC). Considering the role of PI3K and its downstream effectors in cell proliferation, invasion, and survival, it is reasonable to expect that treatment with PI3K inhibitors could control HNSCC onset and progression. Thus, the research question for our review was whether pharmacological inhibition of PI3K affects HNSCC progression. METHODS: In vitro and in vivo studies were selected from six databases. We collected data regarding cell viability, apoptosis, and the regulation of protein expression levels from in vitro studies. For the in vivo studies, we analyzed the reduction in tumor size or gene and protein expression. RESULTS: The included studies showed reduced cell proliferation and apoptosis after treatment with PI3K inhibitors. PI3K inhibitors in combination with other drugs had an enhanced anticancer effects compared to those of single-drug treatments. CONCLUSIONS: The results support the potential of PI3K inhibitors as candidates for clinical trials in HNSCC.


Subject(s)
Head and Neck Neoplasms , Phosphatidylinositol 3-Kinase , Humans , Squamous Cell Carcinoma of Head and Neck/drug therapy , Phosphatidylinositol 3-Kinases/metabolism , Head and Neck Neoplasms/drug therapy , Phosphoinositide-3 Kinase Inhibitors/pharmacology , Cell Proliferation , Cell Line, Tumor
3.
J Dent Res ; 100(12): 1321-1329, 2021 11.
Article in English | MEDLINE | ID: mdl-34324825

ABSTRACT

This is the first update of the previously published living systematic review that summarized evidence on the prevalence of oral signs and symptoms in patients with COVID-19. Hitherto, 183 studies were included, reporting data from 64,876 patients with COVID-19 worldwide. The overall prevalence of taste disorders was 38% (95% CI = 22% to 56%, I2 = 98%). Hypogeusia, dysgeusia, and ageusia were also evaluated by a meta-analysis, and the pooled prevalence was 34% for hypogeusia, 33% for dysgeusia, and 26% for ageusia. Taste disorders were associated with a positive COVID-19 test (odds ratio [OR] = 7.54, 95% CI = 5.24 to 10.86, I2 = 93%, P < 0.00001), showing high certainty of evidence. However, the association between taste disorders and mild/moderate severity of COVID-19 (OR = 1.63, 95% CI = 1.33 to 1.99, I2 = 69%, P < 0.0001) and female patients with COVID-19 (OR = 1.77, 95% CI = 1.26 to 2.48, I2 = 79%, P = 0.001) presented low certainty of evidence. Xerostomia was a new feature of this update, and the pooled data demonstrated a prevalence of 43% (95% CI = 36% to 50%, I2 = 71%) in patients with COVID-19. Regarding oral mucosal lesions, the most common clinical pattern was aphthous like, followed by herpes-like lesions, candidiasis, glossitis/depapillation/geographic tongue, parotitis, and angular cheilitis. Oral lesions were more frequent in the tongue, lips, and palate, presenting miscellaneous clinical aspects that are more likely to represent coinfections. Therefore, the reanalysis of current evidence suggests the triad xerostomia, taste dysfunction, and oral mucosal lesions as common manifestations in patients with COVID-19. However, these outcomes are under discussion, and more studies will be necessary to confirm their association with direct SARS-CoV-2 infection in the oral cavity.


Subject(s)
Ageusia , COVID-19 , Female , Humans , Prevalence , SARS-CoV-2 , Taste Disorders
4.
J Dent Res ; 100(2): 141-154, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32914677

ABSTRACT

This living systematic review aims to summarize evidence on the prevalence of oral signs and symptoms in patients with COVID-19. The review was reported per the PRISMA checklist, and the literature search was conducted in 6 databases and in gray literature. Studies published in any language mentioning oral symptoms and signs in patients with COVID-19 were included. The risk of bias was assessed by the Joanna Briggs Institute appraisal tools. The certainty of evidence was evaluated through GRADE assessment. After a 2-step selection, 40 studies were included: 33 cross-sectional and 7 case reports. Overall, 10,228 patients (4,288 males, 5,770 females, and 170 unknown) from 19 countries were assessed. Gustatory impairment was the most common oral manifestation, with a prevalence of 45% (95% CI, 34% to 55%; I2 = 99%). The pooled eligible data for different taste disorders were 38% for dysgeusia and 35% for hypogeusia, while ageusia had a prevalence of 24%. Taste disorders were associated with COVID-19 (odds ratio [OR], 12.68; 95% CI, 6.41 to 25.10; I2 = 63%; P < 0.00001), mild/moderate severity (OR, 2.09; 95% CI, 1.25 to 3.49; I2 = 66%; P = 0.005), and female patients (OR, 1.64; 95% CI, 1.23 to 2.17; I2 = 70%; P = 0.0007). Oral mucosal lesions presented multiple clinical aspects, including white and erythematous plaques, irregular ulcers, small blisters, petechiae, and desquamative gingivitis. Tongue, palate, lips, gingiva, and buccal mucosa were affected. In mild cases, oral mucosal lesions developed before or at the same time as the initial respiratory symptoms; however, in those who required medication and hospitalization, the lesions developed approximately 7 to 24 d after onset symptoms. Therefore, taste disorders may be common symptoms in patients with COVID-19 and should be considered in the scope of the disease's onset and progression. Oral mucosal lesions are more likely to present as coinfections and secondary manifestations with multiple clinical aspects (PROSPERO CRD42020184468).


Subject(s)
COVID-19/complications , Mouth Diseases/virology , Mouth Mucosa/pathology , Taste Disorders/virology , Cross-Sectional Studies , Female , Humans , Male , Mouth Diseases/pathology , Mouth Mucosa/virology , Prevalence
5.
J Oral Rehabil ; 45(5): 414-422, 2018 May.
Article in English | MEDLINE | ID: mdl-29446485

ABSTRACT

The purpose of this study was to systematically review the literature for studies that assessed the effects of glucosamine supplements (GS) on pain and maximum mouth opening (MMO) restriction compared to other therapies, placebo or no intervention on painful temporomandibular joint osteoarthritis (TMJ OA). Randomised controlled trials were selected in a two-phase process. Seven electronic databases, in addition to three grey literature databases, were searched. Risk of bias was assessed using the Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Twelve potentially eligible studies were identified, from which three were finally included. Furthermore, two were categorised at low risk and one at high risk of bias. Intervention groups were treated with glucosamine-sulphate, while controls were treated with placebo or ibuprofen. In two studies, GS were equally effective regarding pain reduction and mouth opening improvement compared to ibuprofen taken two or three times a day over 12 weeks; however, one study did not find significant differences in follow-up evaluations concerning these clinical variables in both glucosamine and placebo groups administered over six weeks. There is very low evidence regarding GS therapeutic effects on TMJ OA. Considering a follow-up of 12 weeks, GS were as effective as ibuprofen taken two or three times a day. However, over six weeks of medication intake, GS were not superior to placebo. Still, included studies presented major drawbacks, and therefore, conclusions must be interpreted with caution.


Subject(s)
Arthralgia/drug therapy , Glucosamine/therapeutic use , Osteoarthritis/drug therapy , Temporomandibular Joint/drug effects , Arthralgia/physiopathology , Dietary Supplements , Humans , Osteoarthritis/physiopathology , Pain Measurement , Randomized Controlled Trials as Topic , Temporomandibular Joint/physiopathology , Treatment Outcome
6.
Dentomaxillofac Radiol ; 41(5): 396-404, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22241874

ABSTRACT

OBJECTIVES: The aim of the study was to verify the concordance of contrast-enhanced CT (CECT) and MRI evaluation among four radiologists in detecting metastatic cervical lymph nodes of oral cancer patients. METHODS: Ten patients underwent clinical and imaging examinations (CECT and MRI). Four radiologists, two oral and maxillofacial radiologists (OMRs) and two medical radiologists (MRs), independently analysed the images twice. Cohen's kappa index and Wilcoxon signed-rank test were used to verify the concordance between all analyses. RESULTS: Regarding the interobserver agreement, the OMRs presented excellent kappa values for determining the regional lymph nodes (N-stage) in both CECT and MRI. The MRs presented moderate agreement for CECT evaluation at the first reading, but no concordance was found for the other analyses. When each imaging modality was analysed separately, kappa values were higher between all examiners. Greater variability was demonstrated between N-stage evaluation using different examinations. All radiologists were able to identify a greater number of metastatic lymph nodes in CECT than in MRI, except one MR, but no significant difference was found for all readers. The differences between the number of metastatic lymph nodes among all radiologists were not statistically significant. Moderate intraobserver agreement was observed for CECT and MRI evaluation, except for one MR. CONCLUSIONS: The differences found between the N-stage performed by OMRs and MRs support the necessity of a multidisciplinary approach in the imaging evaluation of metastatic nodes. Further studies are necessary to confirm which imaging modality should be employed when evaluating neck areas.


Subject(s)
Carcinoma, Squamous Cell/secondary , Head and Neck Neoplasms/secondary , Lymphatic Metastasis/pathology , Magnetic Resonance Imaging , Mouth Neoplasms/pathology , Neck/pathology , Tomography, X-Ray Computed , Adult , Aged , Carcinoma, Squamous Cell/diagnostic imaging , Contrast Media , Diagnosis, Differential , Female , Head and Neck Neoplasms/diagnostic imaging , Humans , Iopamidol , Lymphatic Metastasis/diagnostic imaging , Male , Middle Aged , Mouth Neoplasms/diagnostic imaging , Neoplasm Staging , Statistics, Nonparametric
7.
Dentomaxillofac Radiol ; 39(3): 140-8, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20203275

ABSTRACT

OBJECTIVES: The aim was to verify the concordance of CT evaluation among four radiologists (two oral and maxillofacial and two medical radiologists) at the TN (tumour/node) stage and in the follow-up of oral cavity and oropharyngeal cancer patients. The study also compared differences between clinical and CT examinations in determining the TN stage. METHODS: The following clinical and tomographic findings of 15 non-treated oral cavity and oropharyngeal cancer patients were compared: tumour size, bone invasion and lymph node metastases. In another 15 patients, who had previously been treated, a clinical and tomographic analysis comparison for the presence of tumoural recurrence, post-therapeutic changes in muscles and lymph node metastases was performed. The concordances of tomographic evaluation between the radiologists were analysed using the kappa index. RESULTS: Significant agreement was verified between all radiologists for the T stage, but not for the N stage. In the group of treated patients, CT disclosed post-therapeutic changes in muscles, tumour recurrence and lymph node metastases, but no concordance for the detection of lymph node metastases was found between radiologists. In the first group, for all radiologists, no concordance was demonstrated between clinical and tomographic staging. CT was effective for delimitating advanced lesions and for detecting lymph node involvement in N0 stage patients. CT revealed two cases of bone invasion not clinically detected. CONCLUSIONS: Interprofessional relationships must be stimulated to improve diagnoses, and to promote a multidisciplinary approach to oral cavity and oropharyngeal cancer. Although CT was important in the diagnosis and follow-up of cancer patients, differences between medical and dental analyses should be acknowledged.


Subject(s)
Carcinoma, Squamous Cell/diagnostic imaging , Mouth Neoplasms/diagnostic imaging , Oropharyngeal Neoplasms/diagnostic imaging , Tomography, X-Ray Computed/methods , Adult , Aged , Carcinoma, Squamous Cell/pathology , Contrast Media , Diagnosis, Differential , Female , Humans , Iopamidol , Lymphatic Metastasis/diagnostic imaging , Male , Middle Aged , Mouth Neoplasms/pathology , Neoplasm Staging , Oropharyngeal Neoplasms/pathology
8.
Arch Oral Biol ; 50(2): 237-42, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15721155

ABSTRACT

A rare syndrome associating amelogenesis imperfecta (AI) with nephrocalcinosis has been reported. The purpose of this study is to characterise the phenotype of a consanguineous family presenting amelogenesis imperfecta, delayed permanent teeth eruption and nephrocalcinosis. Six family members were examined. Ground sections of the case index deciduous teeth and biopsies of enlarged dental follicles were analysed. The patients's parents were first cousins. The case index had yellow discoloration and altered teeth shapes, retention of deciduous teeth, and delayed eruption. Panoramic radiographs revealed multiple enlarged pericoronal follicles in unerupted teeth and generalised intrapulpal calcifications. Renal ultrasound showed the presence of nephrocalcinosis. No other family members presented enamel defects or nephrocalcinosis. Histologically, the enamel appeared hypoplastic, and dental follicles indicated pericoronal hamartoma. The consanguineous marriage suggests an autosomal recessive mode of inheritance. Further studies are necessary to clarify the genetic defect behind this syndrome that associates AI, nephrocalcinosis and impaired tooth eruption.


Subject(s)
Amelogenesis Imperfecta/pathology , Consanguinity , Dental Pulp Calcification/pathology , Nephrocalcinosis/pathology , Tooth/pathology , Adolescent , Amelogenesis Imperfecta/diagnostic imaging , Dental Pulp Calcification/diagnostic imaging , Dentition, Permanent , Genes, Recessive , Humans , Male , Nephrocalcinosis/diagnostic imaging , Pedigree , Radiography , Syndrome , Tooth/diagnostic imaging , Tooth Eruption/genetics , Tooth, Deciduous
9.
Dentomaxillofac Radiol ; 31(3): 182-6, 2002 May.
Article in English | MEDLINE | ID: mdl-12058266

ABSTRACT

OBJECTIVE: To determine whether spontaneous resolution of simple bone cysts (SBC) is possible. METHODS: Ten patients were diagnosed as SBC on clinical and radiographic criteria and followed up for 1 to 7 years (mean 3.8). The degree of resolution was assessed subjectively by four radiologists and objectively by changes in the grey level histogram. RESULTS: All cases remained asymptomatic over the follow-up period. One of the lesions was considered static, two were increased, six remodeled and one resolved. The mean difference in grey levels between the lesion and the contralateral normal mandible decreased in 8 out of 10 cases. CONCLUSION: It is probable that SBC resolves spontaneously. A protocol for clinical and radiographic diagnosis and follow-up is proposed.


Subject(s)
Jaw Cysts/physiopathology , Mandibular Diseases/physiopathology , Adolescent , Bone Remodeling/physiology , Child , Disease Progression , Female , Follow-Up Studies , Humans , Jaw Cysts/diagnostic imaging , Male , Mandibular Diseases/diagnostic imaging , Radiographic Image Interpretation, Computer-Assisted , Radiography, Bitewing , Radiography, Panoramic , Remission, Spontaneous
SELECTION OF CITATIONS
SEARCH DETAIL